

Germany. ¹³Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Germany, German Cancer Consortium (DKTK), Essen, Germany

INTRODUCTION: Malignant rhabdoid tumors (MRT) are highly aggressive neoplasias mostly affecting young children. They are classified as rhabdoid tumors of the central nervous system (ATRT, atypical teratoid rhabdoid tumor), rhabdoid tumors of the kidney (RTK) or extracranial rhabdoid tumors arising from any soft tissue outside the central nervous system (eMRT, extracranial extrarenal MRT). We report a series of four MRTs with cranial nerve involvement. **METHODS:** Patients were identified from a cohort of 132 patients with MRT (2017 – 2021), as part of the European Rhabdoid Registry (EU-RHAB). Diagnosis of MRT was confirmed immunohistochemically with loss of INI1 expression. Details regarding symptoms at first presentation, diagnostic staging, genetic findings, therapy and the course of disease are reported. **REPORT OF CASES/RESULTS:** The series contains two MRT affecting the trigeminal nerve and two cases with third cranial nerve involvement. They were two female and two male patients with a median age of 4.7 years (1-159 months) at diagnosis. Location of the main tumor mass differed between being located intra- and extracerebrally. Metastases at diagnosis occurred in one patient, a germ-line mutation in SMARCB1 was present in two patients. Two patients received therapy according to EU-RHAB recommendations with an incomplete resection, conventional chemotherapy enhanced by intraventricular methotrexate and radiotherapy. Both patients are currently alive with no signs of progression, one of them bearing a germ-line mutation. Two patients received palliative treatment after surgery due to rapid progression. Median overall survival was 17.3 (1.4-53.1) months. **CONCLUSION:** MRT of the cranial nerves affect the peripheral nervous system in close proximity to the brain, thus forming a unique sub-entity between ATRT and eMRT. The selected cases provide insight into the particular challenge regarding clear classification, diagnostics and therapy.

ATRT-15. PRIMORDIAL GERM CELLS IDENTIFIED AS ONE POTENTIAL CELL OF ORIGIN OF MYC RHABDOID TUMORS

Monika Graf¹, Marta Interlandi^{1,2}, Natalia Moreno¹, Rajanya Roy¹, Dörthe Holdhof^{3,4}, Carolin Köbel^{3,4}, Viktoria Melcher¹, Julius Mertins^{5,6}, Thomas K. Albert¹, Dennis Kastrati^{1,7}, Amelie Alfert¹, Till Holsten^{3,6}, Flavia de Faria^{1,8}, Michael Meisterernst⁹, Claudia Rossig¹, Monika Warmuth-Metz⁹, Johannes Nowak^{9,10}, Gerd Meyer zu Hörste¹¹, Chloe Mayère^{12,13}, Serge Nef^{12,13}, Pascal Johann^{14,15}, Michael C. Frühwald¹⁴, Martin Dugas^{2,16}, Ulrich Schüller^{4,17}, Kornelius Kerl¹; ¹Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany. ²Institute of Medical Informatics, University of Münster, Münster, Germany. ³Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ⁴Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ⁵Department of Neurology, Schlosspark-Klinik, Berlin, Germany. ⁶Institute of Molecular Tumor Biology, University of Münster, Münster, Germany. ⁷Human Genetics, Faculty of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany. ⁸Department of Pediatric Hematology and Oncology, Children's Hospital of Brasilia, Brasilia, Brazil. ⁹Neuroradiological Reference Center, University Hospital Würzburg, Würzburg, Germany. ¹⁰SRH Poliklinik Gera GmbH, Radiological Practice Gotha, Gotha, Germany. ¹¹Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany. ¹²Department of Genetic Medicine and Development, University of Geneva, Geneva, Switzerland. ¹³iGE³, Institute of Genetics and Genomics of Geneva, University of Geneva, Geneva, Switzerland. ¹⁴Swabian Children's Cancer Center, Paediatric and Adolescent Medicine, University Medical Center Augsburg, Augsburg, Germany. ¹⁵Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. ¹⁶Institute of Medical Informatics, Heidelberg University Hospital, Heidelberg, Germany. ¹⁷Research Institute Children's Cancer Center, Hamburg, Germany

Rhabdoid tumors (RT) are embryonal neoplasms occurring most frequently in the central nervous system where they are termed atypical teratoid rhabdoid tumor (ATRT). A common hallmark of RT is homozygous loss of the BAF complex subunit SMARCB1. RT patients have a poor prognosis with an overall survival time of 17 months and >60% of patients suffer from relapses. The lack of an optimal treatment strategy could be attributed to the heterogeneity within and between different subgroups of ATRT. Despite the recent advancements in characterizing RT at a molecular level, the cellular origin of RT remains elusive. Thus, this study focused on the identification of the cellular origin of MYC-RT and underlying epigenetic deregulations which account for the cellular heterogeneity in these tumors. We showed that *Smadcb1* abrogation in *Sox2*-positive progenitor cells at E6.5 give rise to RT of the MYC and SHH subgroup in genetically engineered mouse models (GEMM). To uncover distinct cells of origin (COO) for the SHH and MYC subgroups, unbiased computational approaches were used to com-

pare single-cell transcriptomes of GEMMs with single-cell reference maps of murine early embryogenesis. While SHH tumors arise from mid/hind-brain progenitor cells, primordial germ cells (PGCs) emerge as COO of both intracranial and extracranial MYC tumors. PGCs as COO of MYC-RT were validated *in vivo* by using PGC-specific *Smadcb1* knockout mouse model. We further characterized a deregulated transcriptome in MYC-RT compared to PGCs, which is sustained by a subset of epigenetically driven tumor cells. Deregulated expression of genes driving methylation/demethylation processes in MYC tumors and regression of these tumors upon treatment with decitabine *in vitro* and *in vivo*, indicates that DNA methylation plays a key role in cellular transformation and development of MYC-RT.

ATRT-16. MECHANISMS OF MYELOID CELL-INDUCED RESISTANCE IN AT/RT

Alina Disch¹, Viktoria Melcher¹, Carolin Walter^{1,2}, Marta Interlandi^{1,2}, Natalia Moreno¹, Flavia W. de Faria¹, Monika Graf¹, Martin Hasselblatt³, Thomas K. Albert¹, Kornelius Kerl¹; ¹Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany. ²Institute of Medical Informatics, University of Münster, Münster, Germany. ³Institute of Neuropathology, University Hospital Münster, Münster, Germany

INTRODUCTION: Atypical teratoid/rhabdoid tumor (AT/RT) is a primary pediatric tumor entity of the central nervous system showing intra- and intertumoral heterogeneity concerning the molecular landscape and cellular composition. Myeloid cells are considered key orchestrators of the immunological tumor microenvironment (TME) of AT/RT. Tumor-infiltrating CD68⁺ macrophages favor chemotherapy resistance and recurrence, and are consequently related to a poor patient outcome. **METHODS:** Using single-cell RNA sequencing (scRNA-seq) of human and murine AT/RT samples, multiplex immunohistochemistry, depletion of myeloid cells in mouse models and advanced cell culture models for myeloid tumor cell communication, we obtained deeper mechanistic insight into these cell-cell interactions. **RESULTS:** Infiltrating CD68⁺ macrophages interact with AT/RT tumor cells generating intermediary hybrid-like cells with autonomous communication properties, increasing the cell heterogeneity of AT/RT. By depletion of myeloid cells in AT/RT mouse models followed by scRNA-seq of tumor and non-tumor samples, we demonstrated that tumor formation is hindered. Furthermore, we give mechanistic insights into how myeloid cells contribute to tumorigenesis. **IN CONCLUSION:** the dynamic and extensive interactions between tumor cells and myeloid cells do not only potentiate cellular heterogeneity but might also induce cellular plasticity associated with the acquisition of resistance to chemotherapy and seem to be essential for AT/RT development.

ATRT-17. A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMOURS AND ATYPICAL TERATOID RHABDOID TUMOURS.

Paul Wood^{1,2}, Jayesh Desai^{3,4}, Kelly Waldeck^{5,6}, Jason Cain⁷, Nicholas Gottardo^{8,9}, Robyn Strong¹⁰, Kathryn Kinross¹⁰, Michelle Carr¹⁰, Janelle Jones¹⁰, Lily Wong¹¹, David Ziegler¹², Jordan Hansford^{13,14}, Michael Michael³, David Ashley¹⁵; ¹Monash Health, Clayton, Australia. ²Department of Paediatrics, Monash University, Clayton, Australia. ³Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. ⁴Australia and New Zealand Sarcoma Association (ANZSA), Melbourne, Australia. ⁵Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia. ⁶Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. ⁷The Hudson Institute of Medical Research, Clayton, Australia. ⁸Perth Children's Hospital, Perth, Australia. ⁹Brain Tumour Research Program, Telethon Kid's Institute, Perth, Australia. ¹⁰Australian & New Zealand Children's Haematology/Oncology Group (ANZCHOG), Melbourne, Australia. ¹¹Kids Oncology and Leukaemia Trials (KOALA), Randwick, Australia. ¹²Sydney Children's Hospital, Randwick, Australia. ¹³Michael Rice Cancer Centre, Woman's and Children's Hospital, Adelaide, Australia. ¹⁴South Australia Health and Medical Research Institute and South Australian Immunogenomics Cancer Institute, Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia. ¹⁵The Preston Robert Tisch Brain Tumor Centre, Duke University Medical School, Durham, North Carolina, USA

BACKGROUND: Panobinostat treatment has been shown to terminally differentiate malignant rhabdoid tumours (MRT) and atypical teratoid rhabdoid tumours (ATRT) in pre-clinical models. We report results of the open label, phase II study of oral panobinostat in patients with newly diagnosed or relapsed MRT/ATRT. **AIMS:** To assess the anti-tumour activity of low dose, continuous oral panobinostat as well as its associated toxicities. To assess the biological activity of low dose panobinostat by measuring histone H4 acetylation status in peripheral mononuclear cells (PMNC), and differentiation markers. **METHODS:** Following primary institutional standard of care induction and

consolidation chemotherapy and/or radiation treatment, patients were enrolled and commenced on panobinostat as a continuous daily oral dose starting at 10mg/m²/day, with a three-week wash out period between therapies. Real-time acetylation status, measuring acetylated H4 on PMNC, was performed to determine the pharmacodynamics of panobinostat at different dosing levels. Patients were monitored for toxicity; dose reductions were in decrements of 2mg/m²/day. RESULTS: A total of 13 patients with newly diagnosed ATRT/MRT and one patient with relapsed MRT have been enrolled. The average age at enrollment was 3.6 years (range 0.8-6.8 years). The mean treatment duration was 206 days (13-344 days). Currently, six patients (42.9%) remain on study with a mean study duration of 531 days (range 13-895 days). 6/14 patients (42.9%) were removed due to disease progression at a mean study duration of 245 days (44-560 days). 2/14 patients (14.3%) withdrew due to toxicity. 12/14 patients (85.7%) required dose reductions. The main toxicities were thrombocytopenia and leukopenia (Grade III-IV). Real-time pharmacodynamic assessment of panobinostat, at a dose as low as 6mg/m²/day resulted in significant acetylation of histone H4 in PMNC. CONCLUSIONS: Treatment with low dose panobinostat is well tolerated in infants and children with MRT/ATRT, with significant acetylation of histone H4 in PMNC.

ATRT-18. ATYPICAL TERATOID/RHABDOID TUMOR IN CHILDREN: CASE REPORTS FROM INDONESIA

Diko Anugrah Ramadhan¹, Wanda Gautami¹, Ludi Dhyani Rahmartani¹, Ahmad Raffi¹, Kevin Gunawan², Mohamad Yanuar Amal³, Eka Susanto⁴, Handoko Handoko⁵; ¹Department of Child Health, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital,, Jakarta, DKI Jakarta, Indonesia. ²Department of Neurosurgery, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia. ³Department of Radiology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia. ⁴Department of Pathological Anatomy, Faculty of Medicine Universitas Indonesia, Jakarta, DKI Jakarta, Indonesia. ⁵Department of Radiotherapy, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia

Atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system is a sporadic and highly malignant tumor that usually affects very young children and is typically deadly despite very aggressive treatment. The optimal treatment for AT/RT remains unclear, including surgery, radiotherapy, and chemotherapy. Here we report cases of AT/RT in Indonesia. Case 1: A three-year-old girl came with worsening intermittent headaches with projectile vomiting, progressive and insidious right spastic hemiparesis, and slowly progressive weight loss three months before admission. She had septate multiloculated hydrocephalus. Head MRI demonstrates a solid lobulated mass with heterogeneous enhancement and MRS shows an aggressive metabolite pattern, arising from posterior fossa extending into the cerebellum and cerebellopontine angle, causing severe obstructive hydrocephalus. She underwent tumor resection with a midline suboccipital approach, then continued with craniospinal irradiation with dose of 36 Gy in 20 fractions then followed by 18 Gy in 10 fractions booster to posterior fossa, making the total dose to posterior fossa (the tumor) to be 54 Gy. Case 2: A twenty-month-old baby with a history of recurrent seizures, tremors, and less activity in the last two months. She had spasticity with hyperreflexia. She has been referred to our center for further evaluation and management after biopsy and VP shunt surgery at the previous hospital. Head CT scan demonstrates a large solid heterogeneous mass in the right hemisphere cerebral, causing midline shift and hydrocephalus. After the VP shunt was repaired, she underwent Head Start III chemotherapy protocol cycle 1. Both pathology examinations of the patients revealed a hypercellular tumor with prominent hyperchromatic nucleoli and loss of INI-1 staining on immunohistochemistry consistent with an ATRT diagnosis. Unfortunately, both patients died due to severe sepsis after treatment. Although AT/RT has become increasingly recognized, prognosis of ATRT is generally unfavorable, especially in developing countries.

ATRT-19. FUNCTIONAL GENOMICS REVEAL DISTINCT MODULATORS OF RESPONSE TO CDK4/6 INHIBITORS IN ATRTS

Daniel Merk^{1,2}, Sohpie Hirsch^{1,2}, Foteini Tsiami^{1,2}, Bianca Walter^{1,2}, Lara Haeusser^{1,2}, Sepideh Babaei², Jakob Admard², Nicolas Casadei², Cristiana Roggia², Michael Spohn³, Jens Schittenhelm², Stephan Singer², Ulrich Schüller³, Federica Piccioni⁴, Nicole Persky⁴, David Roor⁴, Manfred Claassen², Marcos Tatagiba², Ghazaleh Tabatabai²; ¹Hertie Institute for Clinical Brain Research, Tübingen, Germany. ²University Hospital Tübingen, Tübingen, Germany. ³Research Institute Children's Cancer Center, Hamburg, Germany. ⁴Broad Institute of MIT and Harvard, Cambridge, USA

Brain tumors are the leading cause of cancer-related deaths in children, and atypical teratoid rhabdoid tumors (ATRTs) are among the most common aggressive brain tumors in infants. With no standard-of-care treatment so far, ATRTs continue to have relatively low survival estimates, illustrating the urgent need for more efficacious treatment options. We have previously used genome-wide CRISPR/Cas9 knockout screens in combin-

ation with small-molecule drug assays to identify targetable vulnerabilities in ATRTs. CDK4/6 inhibitors, among the most promising drugs in our study with direct translational potential, are capable of inhibiting tumor growth due to mutual exclusive dependency of ATRTs on either CDK4 or CDK6. We here used genome-wide loss-of-function and gain-of-function strategies to identify modulators of response to CDK4/6 inhibition in ATRTs. Of note, while some well-known resistance mechanisms such as loss of RB1 or FBXW7 are shared by ATRT cell lines, we have also identified modulators of response to CDK4/6 inhibition with opposing effects across ATRT cell lines. As such, loss of AMBRA1, a recently described master regulator of D type cyclins, can either oppose the effects of or synergize with CDK4/6 inhibitors based on the cellular background. We are currently using a proteomics approach to further delineate the mechanism driving this functional heterogeneity of AMBRA1 in ATRTs. Our study will therefore provide deeper insights into the response of ATRTs to CDK4/6 inhibitors, which represent one of the most promising class of targeted agents for the treatment of ATRTs.

ATRT-20. NOVEL PROGNOSTIC MOLECULAR SIGNATURES FOR IMPROVED RISK-CLASSIFICATION OF ATYPICAL TERATOID RHABDOID TUMOURS

Claire Keeling¹, Yura Grabovska², Patricia O'Hare^{3,4}, Stephen Crosier¹, Jessica C Pickles^{4,5}, Martina A Finetti^{6,1}, Amy R Fairchild^{4,5}, John Anderson^{3,4}, Darren Hargrave^{3,4}, Bernadette Brennan⁷, Thomas S Jacques^{4,5}, Steven C Clifford¹, Simon Bailey^{1,8}, Daniel Williamson¹; ¹Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom. ²The Institute of Cancer Research, London, United Kingdom. ³UCL Great Ormond Street Institute of Child Health, London, United Kingdom. ⁴Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. ⁵UCL, Great Ormond Street Institute of Child Health, London, United Kingdom. ⁶Leeds University, Leeds, United Kingdom. ⁷Royal Manchester Children's Hospital, Manchester, United Kingdom. ⁸Great North Children's Hospital, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

Malignant Rhabdoid Tumours (MRT) are aggressive paediatric malignancies seen in the central nervous system (Atypical Teratoid Rhabdoid Tumours (ATRT)), and kidney and other soft tissues (Extra-cranial Rhabdoid Tumours (ECRT)). With current therapies often proving ineffective and a lack of clear prognostic associations with consensus subgroups, we explored the possibility of using prognostic molecular signatures to further identify the biological characteristics of high risk ATRT patients. By employing a cross-validated feature selection method the methylation profiles of 121 MRT patients were analysed with clinical data to obtain meta-CpG signatures associated with prognosis for ATRT, ECRT and MRT. The relationship between these meta-CpG signatures and the consensus subgroups were further explored, along with the correlation of meta-CpGs with gene expression to establish biological significance. By selecting CpGs for their ability to predict survival this method obtained three novel prognostic methylation signatures which predict MRT outcome (ATRT-5, ECRT-14 and MRT-42). These signatures are independent of molecular subgroup and each signature was significantly associated with overall survival (OS) and event free survival (EFS) in their respective cohorts (p<0.001). Both ATRT-5 and MRT-42 maintained their significant association with OS in an independent ATRT cohort (n=64) and each meta-CPG signature is prognostically independent of other major clinical risk factors (e.g. receipt of radiotherapy and presence of metastases). Biologically, individuals with high-risk methylation signatures showed a gene expression profile suggestive of higher proliferative rates and tumours with low-risk scores in ATRT-5 and MRT-42 had an upregulated inflammatory response and increased immune infiltration. Combining these meta-CpGs with other significant clinical risk-factors produced high performing multivariate Cox-models enabling us to propose new stratification models for ATRT and MRT patients. These subgroup-independent prognostic signatures represent a distinct biology in ATRT and, if validated in prospective studies, could progress the use and efficacy of precision-based medicine in this therapeutically challenging disease.

ATRT-21. CONTRIBUTION OF GERMLINE MOSAIC ALTERATIONS OF SMARCB1 IN RHABDOID TUMOR PREDISPOSITION SYNDROME

Julien Masliyah-Planchon¹, Laetitia Maillot¹, Noémie Rybak¹, Fatoumata Simaga², Abderraouf Hamza¹, Marion Gauthier Villars², Olivier Delattre¹, Franck Bourdeaut³; ¹Oncogenetic department, Institut Curie, Paris, France. ²Clinical Oncogenetic, Institut Curie, Paris, France. ³Pediatric department, Institut Curie, Paris, France

Rhabdoid tumors are rare and aggressive tumors that usually arise in very young children. They are characterized by a bi-allelic inactivation of the *SMARCB1* gene. Although the majority of alterations of *SMARCB1* are acquired in tumors, a heterozygous germline alteration is seen in one third of patients and